ODT News and Press, Odonate Therapeutics Inc. From 04/25/19

Odonate Therapeutics (NASDAQ: ODT ): Q1 GAAP EPS of -$1.16. More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2019. As of March 31, 2019, Od...

Gainers: PLAY   +7.6% . OTCQB:HLIX   +3.8% . EVC   +2.8% . PTGX   +2.3% . ODT   +2.1% . More news on: Dave & Buster's Entertainment, Inc., Helix TCS, Inc., Entravision Communications Corporation, Stocks on the move, Read more ...

- Results Presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 - Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer,...

- Study Will Investigate Tesetaxel-Immuno-Oncology (IO) Combinations in Patients with Metastatic Triple-Negative Breast Cancer (TNBC) - - First Randomized Clinical Study to Compare Three Approved PD-(L)1 Inhibitors - - Study Also Will Investigate Tesetaxel Monotherapy in Elde...

Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019, at...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated CONTESSA 2, a multinational, multicenter, Phase 2 study of tesetaxe...

- In Preclinical Testing, Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time - Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and...